Care Access Research Collaborates with AstraZeneca on Phase III Clinical Trial for COVID-19 Long-Acting Antibody Combination
(BUSINESS WIRE) — Care Access Research, a decentralized research organization (DRO) that operates as one connected team of physicians and research experts, today announced a collaboration with global biopharmaceutical company AstraZeneca to accelerate a clinical trial in the US for AZD7442, AstraZeneca’s long-acting monoclonal antibody (LAAB) combination for the potential prevention of COVID-19
Read More